The estimated Net Worth of David T Howton is at least $10.6 Million dollars as of 2 December 2023. Mr. Howton owns over 13,051 units of Sarepta Therapeutics Inc stock worth over $1,675,618 and over the last 13 years he sold SRPT stock worth over $4,679,727. In addition, he makes $4,196,620 as Executive Vice President, General Counsel, and Secretary at Sarepta Therapeutics Inc.
Sign up
Mr. Howton SRPT stock SEC Form 4 insiders trading
David has made over 12 trades of the Sarepta Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 13,051 units of SRPT stock worth $1,675,618 on 2 December 2023.
The largest trade he's ever made was exercising 105,122 units of Sarepta Therapeutics Inc stock on 22 June 2020 worth over $2,707,943. On average, David trades about 11,502 units every 144 days since 2011. As of 2 December 2023 he still owns at least 13,051 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Mr. Howton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Howton biography
David Tyronne Howton Jr. serves as Executive Vice President, General Counsel, Secretary of the Company. Mr. Howton has served as our Executive Vice President, General Counsel and Corporate Secretary since February 2019. Prior to this appointment, he served as Senior Vice President, General Counsel and Corporate Secretary from November 2012 to February 2019. From September 2011 to November 2012, Mr. Howton served as the Senior Vice President, Chief Legal Officer and as a member of the executive team at Vertex Pharmaceuticals Incorporated, a publicly-traded biotechnology company. In this capacity, he participated in the general management of the company and oversaw all aspects of the Vertex global legal and compliance departments. Prior to his appointment as Chief Legal Officer at Vertex, Mr. Howton served as the Chief Compliance Officer from September 2009 to August 2011 and, in this capacity, he was responsible for designing and implementing the Vertex corporate compliance program as well as chairing the company’s Corporate Compliance Committee. From 2003 to September 2009, Mr. Howton worked at Genentech, Inc., a biotechnology company, where he served in a number of legal roles before becoming the company’s Chief Healthcare Compliance Officer in 2006. Prior to joining Genentech in 2003, Mr. Howton was a member of the Sidley Austin LLP corporate healthcare practice, where he advised clients on corporate transactions involving life science companies and provided regulatory counsel. Mr. Howton holds a Bachelor of Arts (B.A.) from Yale University and a J.D. from Northwestern University School of Law.
What is the salary of David Howton?
As the Executive Vice President, General Counsel, and Secretary of Sarepta Therapeutics Inc, the total compensation of David Howton at Sarepta Therapeutics Inc is $4,196,620. There are 2 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.
How old is David Howton?
David Howton is 48, he's been the Executive Vice President, General Counsel, and Secretary of Sarepta Therapeutics Inc since 2019. There are 14 older and 3 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
What's David Howton's mailing address?
David's mailing address filed with the SEC is C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN, MA, 02129.
Insiders trading at Sarepta Therapeutics Inc
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry, and M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
What does Sarepta Therapeutics Inc do?
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
What does Sarepta Therapeutics Inc's logo look like?
Complete history of Mr. Howton stock trades at Sarepta Therapeutics Inc, Vertex Pharmaceuticals, and Solid Biosciences Inc
Sarepta Therapeutics Inc executives and stock owners
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Gilmore O'Neill,
Executive Vice President, R&D and Chief Medical Officer -
William Ciambrone,
Executive Vice President - Technical Operations -
David Howton,
Executive Vice President, General Counsel, Secretary -
Alexander Cumbo,
Executive Vice President and Chief Commercial Officer -
Douglas Ingram,
President, Chief Executive Officer, Director -
Douglas S. Ingram,
Pres, CEO & Director -
Dr. Gilmore O'Neill M.D.,
Exec. Officer -
Dr. Louise Rodino-Klapac Ph.D.,
Chief Scientific Officer and Head of R&D -
Ian Michael Estepan,
Exec. VP & CFO -
William F. Ciambrone,
Exec. VP of Technical Operations -
M. Kathleen Behrens,
Independent Chairwoman of the Board -
Richard Barry,
Independent Director -
Hans Wigzell,
Independent Director -
Claude Nicaise,
Independent Director -
Mary Gray,
Independent Director -
John Martin,
Independent Director -
Joseph Bratica,
Interim Principal Financial and Accounting Officer -
Dr. Diane L. Berry,
Sr. VP of Global Health Policy and Gov. & Patient Affairs -
Alison Nasisi,
Chief People Officer & VP -
Ryan E. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Mary Jenkins,
Sr. Mang. of Investor Relations -
Michael W Bonney,
Director -
Ben Gil Price,
Director -
Catherine Stehman Breen,
SVP, Chief Medical Officer -
Jayant Aphale,
SVP Technical Operations -
Jean Paul Kress,
Director -
William Alden Goolsbee,
Director -
Shamim Ruff,
SVP, Chief Regulatory Affairs -
Sandesh Mahatme,
EVP, CFO & CBO -
Guriqbal S. Basi,
SVP, Chief Scientific Officer -
Michael A Jacobsen,
VP of Finance and PAO -
Anthony Martignetti,
-
Nishan Garabedian Christopher,
President and CEO -
Anthony R Chase,
Director -
John Hodgman,
Director -
Arthur M Krieg,
SVP, Chief Scientific Officer -
Edward M. Md Kaye,
SVP & Chief Medical Officer -
Ian Michael Estepan,
Chief Financial Officer -
Ryan Edward Brown,
EVP, General Counsel -
Louise Rodino Klapac,
Head of R&D, CSO -
Bilal Arif,
Chief Tech Ops Officer -
Stephen Mayo,
-
Kathryn Jean Boor,
-
Dallan Murray,
Chief Customer Officer